Methods for determining carrier status

ABSTRACT

The invention generally relates to methods for determining carrier status with respect to a condition or disease. In certain embodiments, the method involves exposing a sample to a plurality of molecular inversion probes capable of capturing DNA from at least one genomic region suspected of having an altered copy number and at least one internal control DNA known or suspected to have a stable copy number, capturing and sequencing DNA that binds to the molecular inversion probes, and determining a copy number state of the at least one genomic region based on the sequence results.

FIELD

The present invention relates generally to genetic testing, and, more particularly, to methods for determining carrier or disease status with respect to a particular disease or condition.

BACKGROUND

Genetic counseling is the process by which individuals, typically prospective parents, are advised regarding the likelihood of transmitting an inherited or genetic disorder to any future offspring. To assist in the process, individuals seeking counseling typically undergo a number of tests that assess indications of genetic disorders. These tests may include, for example, screening assays that detect clinically significant variations in various biomarkers. For example, carrier screening can determine if members of a couple are both carriers of a recessive genetic disorder. With this information, the couple can learn or rule out that they are at risk for having children with the genetic disorder.

Some currently available tests screen for autosomal recessive disorders, including spinal muscular atrophy (SMA). Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of motor neurons in the anterior horn of a spinal cord, leading to muscular paralysis and atrophy. The prognosis for SMA may vary on an individual basis. However, the majority of patients children diagnosed with SMA do not reach the age of 10. SMA is the second most common autosomal recessive inherited disorder in humans and the most common genetic cause of infant mortality.

SMA is caused by the homozygous deletion or mutations of the survival motor neuron gene (SMN), including telomeric SMN (SMN1) and centromeric SMN (SMN2) genes. SMA has a carrier frequency of approximately 1 in 40, which is attributable primarily to SMN1 copy number loss produced by either deletion of part or all of SMN1, or conversion of SMN1 to the SMN2 gene, a linked paralog that encodes an identical protein but is poorly expressed due to a silent coding variant that disrupts proper splicing.

Current methods for clinical SMA carrier screening include multiplex ligation-dependent probe amplification (MLPA) for assessing the copy number state of SMN1 in a manner that distinguishes between SMN1 and SMN2, typically by interrogating the exon 7 variant that differs between the paralogs. MLPA is a variation of multiplex polymerase chain reaction (PCR) and permits multiple targets to be amplified with only a single primer pair.

Although current MLPA-based carrier screening assays may be relatively sensitive and specific, they have significant drawbacks. For example, one problem with current MLPA-based assays is that they generally quantify only the nucleotide difference in exon 7 of the SMN1/SMN2 genes. However, it has been found that SMA in approximately 6% of affected patients is caused by point mutations at other exons in which SMN1 is present. As such, MLPA-based assays may miss detection of such point mutations, possibly resulting in inaccurate screening results. Another problem is that MLPA-based assays are time consuming and relatively low-throughput.

SUMMARY

The invention solves problems associated with current carrier screening assays by providing molecular inversion probes for capturing at least one genomic region known or suspected to be associated with a disease and subsequently sequencing the captured DNA to determine the copy number state of the captured DNA. In certain aspects, the captured DNA may be sequenced by known high-throughput sequence methods or techniques. The carrier status for the disease can then be determined based on the identified copy number state. In particular, the copy number state may be indicative of whether the patient is a carrier of a particular disease or condition for which copy number variation is diagnostic, such as an autosomal recessive trait (e.g., spinal muscular atrophy). For example, it can be determined whether copy number variation exists in the genomic regions of interest based on the identified copy number, thereby providing a method for determining whether the patient is a carrier of such an autosomal recessive trait.

Accordingly, the invention overcomes the problems of current carrier screening assays, particularly MLPA-based assays, based, at least in part, on compatibility with automated high-throughput screening. In particular, the invention provides the sensitivity and specificity for detection of copy number variation in SMN1 and/or SMN2, similar to MLPA-based methods, by utilizing molecular inversion probes. Additionally, by using high-throughput screening methods, the invention allows detection of deleterious SMN1 point mutations and indels that would otherwise be missed by MLPA and related approaches, thereby providing more reliable and accurate diagnosis.

In certain aspects, the invention provides a method for determining copy number state of one or more genes in a sample. The method includes exposing a sample to a plurality of molecular inversion probes capable of capturing DNA from at least one genomic region suspected of having an altered copy number, and at least one internal control DNA known or suspected to have a stable copy number. The at least one genomic region may be associated with a particular locus, such as, for example, SMN1 or SMN2, that is associated with a condition or disease.

In embodiments that utilize molecular inversion probes, any molecular inversion probe may be used. An exemplary MIP is a single-stranded probe about 70 nucleotides in length, composed of a universal core of 30 nucleotides that is flanked by specific 20-nucleotide targeting sequences on each side, i.e. targeting arms. However, the length and composition of the probe can vary to most adequately capture the desired target sequence. The targeting arms are designed to hybridize to specific genomic regions upstream and downstream of a target sequence of interest located on the nucleic acid fragment. After the target sequence of interest is isolated between the target arms, the target sequence can be analyzed. Although each MIP captures one target of interest for analysis, multiple probes can be combined into a single vessel containing sample for a multiplexed assay that simultaneously examines multiple target loci.

Upon capturing DNA that binds the molecular inversion probes, the captured DNA is sequenced and further analyzed to determine copy number state for use in determining carrier status of a disease in which copy number variation is diagnostic. The sequencing results in a plurality of reads for both the genomic region suspected of having an altered copy number and the internal control DNA.

Read counts obtained in the sequencing step are normalized for the genomic region with respect to the internal control DNA. The normalized read counts for the genomic region and the control DNA are compared with one another to obtain a ratio of normalized read count of genomic regions of interest/normalized read count of internal control DNA. The copy number state of the genomic region can then be determined based upon the ratio (i.e. difference between the normalized read counts).

The copy number state can be used to determine the carrier status of an individual from which the sample was obtained. In particular, the copy number state may be indicative of whether the patient is a carrier of a particular disease or condition for which copy number variation is diagnostic. Copy-number variations (CNVs), a form of structural variation, are alterations of the DNA of a genome that results in the cell having an abnormal number of copies of one or more sections of the DNA. CNVs correspond to relatively large regions of the genome that have been deleted (fewer than the normal number) or duplicated (more than the normal number) on certain chromosomes. Some diseases are associated with CNVs of particular genes or gene fragments. For example, copy number variation in the SMN1 and/or SMN2 gene is closely associated with spinal muscular atrophy (SMA), an autosomal recessive trait. Accordingly, variation in the copy number state may indicate the presence of an autosomal recessive trait, thereby determining that the patient is a carrier of such an autosomal recessive trait.

In certain aspect, it can be determined whether copy number variation exists in the genomic regions of interest based on the calculated ratio of normalized read count of genomic regions of interest/normalized read count of internal control DNA. For example, copy number variation generally exists if there is a statistical difference between the normalized read counts for the genomic region the control DNA (i.e. a ratio outside of a range of 0.8 to 1.2). Similarly, copy number variation does not exist if there is little or no statistical difference between the normalized read counts for the genomic region the control DNA (i.e. a ratio within the range of 0.8 to 1.2).

The invention may be used to determine carrier status for other autosomal recessive traits, including, but not limited to, cystic fibrosis, sickle cell anemia, tay sachs disease, Familial hyperinsulinism, Canavan Disease, Maple Syrup Urine Disease, Bloom's Syndrome, Usher Syndrome type IIIA, Dihydrolipoamide dehydrogenase deficiency, Fanconi anemia group C, Familial dysautonomia, Mucolipidosis Type IV, Usher Syndrome Type IV, Nieman-Pick disease type A/B, Walker Warburg syndrome, and Joubert Syndrome.

In a related aspect, the invention provides a method of determining copy number between two paralogous genes. The method includes exposing a sample including a first genetic locus, a second genetic locus, and at least one control genetic locus to a plurality of molecular inversion probes. At least some of the probes are capable of hybridizing with one or more of the first genetic locus, the second genetic locus, and the control genetic locus. The first and second genetic locus may be associated with a particular disease for which copy number variation is diagnostic. Upon obtaining DNA that is hybridized to a member of the plurality of molecular inversion probes, the obtained DNA is sequenced (e.g., next-generation sequencing method) and read counts for each of the first genetic locus and the second genetic locus are normalized with respect to the at least one control genetic locus. The normalized read counts for each of the first genetic locus and the second genetic locus are then compared to normalized read counts for one or more control samples with a known number of copies of the first genetic locus and the second genetic locus. Based on the comparison, relative copy numbers of the first genetic locus and the second genetic locus can be determined. The determined copy numbers can then be used to determine the carrier status of an individual from which the sample was obtained (i.e. whether the patient is a carrier of the disease).

In another related aspect, the invention provides a method for the determination of carrier status with respect to one or more conditions. The method includes exposing a sample to a plurality of molecular inversion probes, at least some of which are capable of hybridizing to DNA of a first locus or DNA of a second locus. DNA in the sample that is hybridized to a member of the plurality of probes is obtained and then sequenced (e.g. next-generation sequencing methods) to obtain sequence read counts for the first locus and the second locus. The read counts are normalized with respect to a control locus, the copy number of which is stable or known. The copy number status of the first locus and the second locus is then inferred based, at least in part, on a comparison of the normalized read counts for the first locus and the second locus with a standard.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a diagram of methods of the invention.

FIG. 2 illustrates a system for performing methods of the invention.

DETAILED DESCRIPTION

The invention generally relates to methods for determining carrier status with respect to a condition or disease, particularly an autosomal recessive trait. In certain embodiments, methods of the invention include determining copy number state of one or more genes in a sample. The methods includes exposing a sample to a plurality of molecular inversion probes capable of capturing DNA from at least one genomic region suspected of having an altered copy number, and at least one internal control DNA known or suspected to have a stable copy number. In some embodiments, the at least one genomic region may be associated with a particular locus, such as, for example, SMN1 or SMN2, that is associated with a condition or disease. The methods further include capturing and sequencing DNA that binds to the molecular inversion probes, normalizing read counts obtained in the sequencing step for the least one genomic region with respect to the internal control DNA, and determining a copy number state of the at least one genomic region based on a comparison between the normalized read counts of the genomic region and read counts for a control diploid locus.

By way of overview, methods of the invention involve obtaining one or more samples including nucleic acids. The nucleic acids, including genomic nucleic acids, of each sample are fragmented and/or denatured so as to render the nucleic acid single stranded for hybridization to a capture probe, such as a molecular inversion probe. As described in greater detail herein, each sample is exposed to a plurality of molecular inversion probes to hybridize or bind with at least one genomic region of interest (e.g. locus) located on the nucleic acid fragments. After capture of the genomic region of interest, the captured region is subjected to an enzymatic gap-filling and ligation step, and further subjected to amplification based on sample-specific barcode polymerase chain reaction (PCR). The resulting barcodes PCRs for each sample are then combined into a master pool and quantified. Analysis of the captured regions of interest involves sequencing, e.g., with a next-generation sequencer, and determining copy number states of the genomic regions of interest based on the sequencing readout.

Nucleic acids suitable for use in aspects of the invention include but are not limited to genomic DNA, genomic RNA, synthesized nucleic acids, whole or partial genome amplification product, and high molecular weight nucleic acids, e.g. individual chromosomes. Genomic DNA and genomic RNA constitute the total genetic information of an organism. Genomic nucleic acids molecules are generally large, and in most organisms are organized into DNA—protein complexes called chromosomes, which the exception of viruses that have RNA genomes. Genomic RNA also includes, for example, RNA transcribed from DNA, unprocessed transcripts, mRNAs, and cDNAs. Sometimes the quality and quantity of genomic nucleic acids obtained from samples precludes their usefulness in large scale genotyping studies. To overcome this problem, use of whole genome amplification products and partial genome amplification products allows for characterization of the genome of a sample even if the quantity and quality of the genomic nucleic acid is limited.

Samples and Obtaining Nucleic Acid

In certain aspects, methods of the invention may involve obtaining a sample. The sample is typically a tissue or body fluid that is obtained in any clinically acceptable manner. A tissue is a mass of connected cells and/or extracellular matrix material, e.g. skin tissue, endometrial tissue, nasal passage tissue, CNS tissue, neural tissue, eye tissue, liver tissue, kidney tissue, placental tissue, mammary gland tissue, placental tissue, gastrointestinal tissue, musculoskeletal tissue, genitourinary tissue, bone marrow, and the like, derived from, for example, a human or other mammal and includes the connecting material and the liquid material in association with the cells and/or tissues. A body fluid is a liquid material derived from, for example, a human or other mammal. Such body fluids include, but are not limited to, mucous, blood, plasma, serum, serum derivatives, bile, blood, maternal blood, phlegm, saliva, sweat, amniotic fluid, menstrual fluid, mammary fluid, follicular fluid of the ovary, fallopian tube fluid, peritoneal fluid, urine, and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF. A sample may also be a fine needle aspirate or biopsied tissue. A sample also may be media containing cells or biological material. A sample may also be a blood clot, for example, a blood clot that has been obtained from whole blood after the serum has been removed. Samples are also obtained from the environment (e.g., air, agricultural, water and soil); and research samples (e.g., products of a nucleic acid amplification reaction, or purified genomic DNA, RNA, proteins, etc.).

Isolation, extraction or derivation of genomic nucleic acids is performed by methods known in the art. Isolating nucleic acid from a biological sample generally includes treating a biological sample in such a manner that genomic nucleic acids present in the sample are extracted and made available for analysis. Any isolation method that results in extracted/isolated genomic nucleic may be used in the practice of the present invention.

Nucleic acids may be obtained by methods known in the art. Generally, nucleic acids are extracted using techniques, such as those described in Sambrook, J. Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory.), the contents of which are incorporated by reference herein. Other methods include: salting out DNA extraction (P. Sunnucks et al., Genetics, 1996, 144: 747-756; S. M. Aljanabi and I. Martinez, Nucl. Acids Res. 1997, 25: 4692-4693), trimethylammonium bromide salts DNA extraction (S. Gustincich et al., BioTechniques, 1991, 11: 298-302) and guanidinium thiocyanate DNA extraction (J. B. W. Hammond et al., Biochemistry, 1996, 240: 298-300). Several protocols have been developed to extract genomic DNA from blood.

There are also numerous kits that can be used to extract DNA from tissues and bodily fluids and that are commercially available from, for example, BD Biosciences Clontech (Palo Alto, Calif.), Epicentre Technologies (Madison, Wis.), Gentra Systems, Inc. (Minneapolis, Minn.), MicroProbe Corp. (Bothell, Wash.), Organon Teknika (Durham, N.C.), Qiagen Inc. (Valencia, Calif.), Autogen (Holliston, Mass.); Beckman Coulter (Brea, Calif.), (AutoGenFlex STAR robot with Qiagen FlexiGene chemistry. For example, Autogen manufactures FlexStar automated extraction kits used in combination with Qiagen FlexiGene Chemistry, and Beckeman Coulter manufactures Agencourt GenFind kits for bead-based extraction chemistry. User Guides that describe in detail the protocol(s) to be followed are usually included in all these kits, for example, Qiagen's literature for their PureGene extraction chemistry entitled “Qiagen PureGene Handbook” 3rd Edition, dated June 2011.

After cells have been obtained from the sample, it is preferable to lyse cells in order to isolate genomic nucleic acid. Cellular extracts can be subjected to other steps to drive nucleic acid isolation toward completion by, e.g., differential precipitation, column chromatography, extraction with organic solvents and the like. Extracts then may be further treated, for example, by filtration and/or centrifugation and/or with chaotropic salts such as guanidinium isothiocyanate or urea or with organic solvents such as phenol and/or HCCl₃ to denature any contaminating and potentially interfering proteins. The genomic nucleic acid can also be resuspended in a hydrating solution, such as an aqueous buffer. The genomic nucleic acid can be suspended in, for example, water, Tris buffers, or other buffers. In certain embodiments the genomic nucleic acid can be re-suspended in Qiagen DNA hydration solution, or other Tris-based buffer of a pH of around 7.5.

Depending on the type of method used for extraction, the genomic nucleic acid obtained can vary in size. The integrity and size of genomic nucleic acid can be determined by pulse-field gel electrophoresis (PFGE) using an agarose gel.

In addition to genomic nucleic acids, whole genome amplification product and partial genomic amplification products can be used in aspects of the invention. Methods of obtaining whole genome amplification product and partial genome amplification product are described in detail in Pinter et al. U.S. Patent Publication Number 2004/0209299, and include, for example, generally ligation mediated PCR™, random primed PCR™, strand displacement mediated PCR™, and cell immortalization.

In certain embodiments, a genomic sample is collected from a subject followed by enrichment for genes or gene fragments of interest, for example by hybridization to a nucleotide array. The sample may be enriched for genes of interest using methods known in the art, such as hybrid capture. See for examples, Lapidus (U.S. Pat. No. 7,666,593), the content of which is incorporated by reference herein in its entirety. As will be described in more detail below, a preferable capture method uses molecular inversion probes.

Fragmenting the Nucleic Acid

Nucleic acids, including genomic nucleic acids, can be fragmented using any of a variety of methods, such as mechanical fragmenting, chemical fragmenting, and enzymatic fragmenting. Methods of nucleic acid fragmentation are known in the art and include, but are not limited to, DNase digestion, sonication, mechanical shearing, and the like (J. Sambrook et al., “Molecular Cloning: A Laboratory Manual”, 1989, 2.sup.nd Ed., Cold Spring Harbour Laboratory Press: New York, N.Y.; P. Tijssen, “Hybridization with Nucleic Acid Probes—Laboratory Techniques in Biochemistry and Molecular Biology (Parts I and II)”, 1993, Elsevier; C. P. Ordahl et al., Nucleic Acids Res., 1976, 3: 2985-2999; P. J. Oefner et al., Nucleic Acids Res., 1996, 24: 3879-3889; Y. R. Thorstenson et al., Genome Res., 1998, 8: 848-855). U.S. Patent Publication 2005/0112590 provides a general overview of various methods of fragmenting known in the art.

Genomic nucleic acids can be fragmented into uniform fragments or randomly fragmented. In certain aspects, nucleic acids are fragmented to form fragments having a fragment length of about 5 kilobases or 100 kilobases. In one embodiment, the genomic nucleic acid fragments can range from 1 kilobases to 20 kilobases. Fragments can vary in size and have an average fragment length of about 10 kilobases. However, desired fragment length and ranges of fragment lengths can be adjusted depending on the type of nucleic acid targets one seeks to capture and the design and type of MIP probes. The particular method of fragmenting is selected to achieve the desired fragment length. Numerous non-limiting examples are provided below.

Chemical fragmentation of genomic nucleic acids can be achieved using a number of different methods. For example, hydrolysis reactions including base and acid hydrolysis are common techniques used to fragment nucleic acid. Hydrolysis is facilitated by temperature increases, depending upon the desired extent of hydrolysis. Fragmentation can be accomplished by altering temperature and pH as described below. The benefit of pH-based hydrolysis for shearing is that it can result in single-stranded products. Additionally, temperature can be used with certain buffer systems (e.g. Tris) to temporarily shift the pH up or down from neutral to accomplish the hydrolysis, then back to neutral for long-term storage etc. Both pH and temperature can be modulated to effect differing amounts of shearing (and therefore varying length distributions).

In one aspect, a nucleic acid is fragmented by heating a nucleic acid immersed in a buffer system at a certain temperature for a certain period to time to initiate hydrolysis and thus fragment the nucleic acid. The pH of the buffer system, duration of heating, and temperature can be varied to achieve a desired fragmentation of the nucleic acid. In one embodiment, after a genomic nucleic acid is purified, it is resuspended in a Tris-based buffer at a pH between 7.5 and 8.0, such as Qiagen's DNA hydrating solution. The resuspended genomic nucleic acid is then heated to 65° C. and incubated overnight (about 16-24 hours) at 65° C. Heating shifts the pH of the buffer into the low- to mid-6 range, which leads to acid hydrolysis. Over time, the acid hydrolysis causes the genomic nucleic acid to fragment into single-stranded and/or double-stranded products.

Other methods of hydrolytic fragmenting of nucleic acids include alkaline hydrolysis, formalin fixation, hydrolysis by metal complexes (e.g., porphyrins), and/or hydrolysis by hydroxyl radicals. RNA shears under alkaline conditions, see, e.g. Nordhoff et al., Nucl. Acid. Res., 21 (15):3347-57 (2003), whereas DNA can be sheared in the presence of strong acids or strong bases.

An exemplary acid/base hydrolysis protocol for producing genomic nucleic acid fragments is described in Sargent et al. (1988) Methods Enzymol., 152:432. Briefly, 1 g of purified DNA is dissolved in 50 mL 0.1 N NaOH. 1.5 mL concentrated HCl is added, and the solution is mixed quickly. DNA will precipitate immediately, and should not be stirred for more than a few seconds to prevent formation of a large aggregate. The sample is incubated at room temperature for 20 minutes to partially depurinate the DNA. Subsequently, 2 mL 10 N NaOH ([OH—] concentration to 0.1 N) is added, and the sample is stirred until the DNA redis solves completely. The sample is then incubated at 65° C. for 30 minutes in order to hydrolyze the DNA. Resulting fragments typically range from about 250-1000 nucleotides but can vary lower or higher depending on the conditions of hydrolysis.

Chemical cleavage can also be specific. For example, selected nucleic acid molecules can be cleaved via alkylation, particularly phosphorothioate-modified nucleic acid molecules (see, e.g., K. A. Browne, “Metal ion-catalyzed nucleic Acid alkylation and fragmentation,” J. Am. Chem. Soc. 124(27):7950-7962 (2002)). Alkylation at the phosphorothioate modification renders the nucleic acid molecule susceptible to cleavage at the modification site. See I. G. Gut and S. Beck, “A procedure for selective DNA alkylation and detection by mass spectrometry,” Nucl. Acids Res. 23(8):1367-1373 (1995).

Methods of the invention also contemplate chemically shearing nucleic acids using the technique disclosed in Maxam-Gilbert Sequencing Method (Chemical or Cleavage Method), Proc. Natl. Acad. Sci. USA. 74:560-564. In that protocol, the genomic nucleic acid can be chemically cleaved by exposure to chemicals designed to fragment the nucleic acid at specific bases, such as preferential cleaving at guanine, at adenine, at cytosine and thymine, and at cytosine alone.

Mechanical shearing of nucleic acids into fragments can occur using any method known in the art. For example, fragmenting nucleic acids can be accomplished by hydroshearing, trituration through a needle, and sonication. See, for example, Quail, et al. (November 2010) DNA: Mechanical Breakage. In: eLS. John Wiley & Sons, Chichester. doi:10.1002/9780470015902.a0005 333.pub2.

The nucleic acid can also be sheared via nebulization, see (Roe, B A, Crabtree. J S and Khan, A S 1996); Sambrook & Russell, Cold Spring Harb Protoc 2006. Nebulizing involves collecting fragmented DNA from a mist created by forcing a nucleic acid solution through a small hole in a nebulizer. The size of the fragments obtained by nebulization is determined chiefly by the speed at which the DNA solution passes through the hole, altering the pressure of the gas blowing through the nebulizer, the viscosity of the solution, and the temperature. The resulting DNA fragments are distributed over a narrow range of sizes (700-1330 bp). Shearing of nucleic acids can be accomplished by passing obtained nucleic acids through the narrow capillary or orifice (Oefner et al., Nucleic Acids Res. 1996; Thorstenson et al., Genome Res. 1995). This technique is based on point—sink hydrodynamics that result when a nucleic acid sample is forced through a small hole by a syringe pump.

In HydroShearing (Genomic Solutions, Ann Arbor, Mich., USA), DNA in solution is passed through a tube with an abrupt contraction. As it approaches the contraction, the fluid accelerates to maintain the volumetric flow rate through the smaller area of the contraction. During this acceleration, drag forces stretch the DNA until it snaps. The DNA fragments until the pieces are too short for the shearing forces to break the chemical bonds. The flow rate of the fluid and the size of the contraction determine the final DNA fragment sizes.

Sonication is also used to fragment nucleic acids by subjecting the nucleic acid to brief periods of sonication, i.e. ultrasound energy. A method of shearing nucleic acids into fragments by sonification is described in U.S. Patent Publication 2009/0233814. In the method, a purified nucleic acid is obtained placed in a suspension having particles disposed within. The suspension of the sample and the particles are then sonicated into nucleic acid fragments.

An acoustic-based system that can be used to fragment DNA is described in U.S. Pat. Nos. 6,719,449, and 6,948,843 manufactured by Covaris Inc. U.S. Pat. No. 6,235,501 describes a mechanical focusing acoustic sonication method of producing high molecular weight DNA fragments by application of rapidly oscillating reciprocal mechanical energy in the presence of a liquid medium in a closed container, which may be used to mechanically fragment the DNA.

Another method of shearing nucleic acids into fragments uses ultrasound energy to produce gaseous cavitation in liquids, such as shearing with Diagonnode's BioRuptor®. Cavitation is the formation of small bubbles of dissolved gases or vapors due to the alteration of pressure in liquids. These bubbles are capable of resonance vibration and produce vigorous eddying or microstreaming. The resulting mechanical stress can lead to shearing the nucleic acid in to fragments.

Enzymatic fragmenting, also known as enzymatic cleavage, cuts nucleic acids into fragments using enzymes, such as endonucleases, exonucleases, ribozymes, and DNAzymes. Such enzymes are widely known and are available commercially, see Sambrook, J. Molecular Cloning: A Laboratory Manual, 3rd (2001) and Roberts R J (January 1980). “Restriction and modification enzymes and their recognition sequences,” Nucleic Acids Res. 8 (1): r63-r80. Varying enzymatic fragmenting techniques are well-known in the art, and such techniques are frequently used to fragment a nucleic acid for sequencing, for example, Alazard et al, 2002; Bentzley et al, 1998; Bentzley et al, 1996; Faulstich et al, 1997; Glover et al, 1995; Kirpekar et al, 1994; Owens et al, 1998; Pieles et al, 1993; Schuette et al, 1995; Smirnov et al, 1996; Wu & Aboleneen, 2001; Wu et al, 1998a.

The most common enzymes used to fragment nucleic acids are endonucleases. The endonucleases can be specific for either a double-stranded or a single stranded nucleic acid molecule. The cleavage of the nucleic acid molecule can occur randomly within the nucleic acid molecule or can cleave at specific sequences of the nucleic acid molecule. Specific fragmentation of the nucleic acid molecule can be accomplished using one or more enzymes in sequential reactions or contemporaneously.

Restriction endonucleases recognize specific sequences within double-stranded nucleic acids and generally cleave both strands either within or close to the recognition site in order to fragment the nucleic acid. Naturally occurring restriction endonucleases are categorized into four groups (Types I, II III, and IV) based on their composition and enzyme cofactor requirements, the nature of their target sequence, and the position of their DNA cleavage site relative to the target sequence. Bickle T A, Kruger D H (June 1993). “Biology of DNA restriction”. Microbiol. Rev. 57 (2): 434-50; Boyer H W (1971). “DNA restriction and modification mechanisms in bacteria”. Annu. Rev. Microbiol. 25: 153-76; Yuan R (1981). “Structure and mechanism of multifunctional restriction endonucleases”. Annu. Rev. Biochem. 50: 285-319. All types of enzymes recognize specific short DNA sequences and carry out the endonucleolytic cleavage of DNA to give specific fragments with terminal 5′-phosphates. The enzymes differ in their recognition sequence, subunit composition, cleavage position, and cofactor requirements. Williams R J (2003). “Restriction endonucleases: classification, properties, and applications”. Mol. Biotechnol. 23 (3): 225-43.

Where restriction endonucleases recognize specific sequencings in double-stranded nucleic acids and generally cleave both strands, nicking endonucleases are capable of cleaving only one of the strands of the nucleic acid into a fragment. Nicking enzymes used to fragment nucleic acids can be naturally occurring or genetically engineered from restriction enzymes. See Chan et al., Nucl. Acids Res. (2011) 39 (1): 1-18.

Denaturing the Nucleic Acids

Methods of the invention also provide for denaturing nucleic acid to render the nucleic acid single stranded for hybridization to a capture probe, such as a MIP probe. Denaturation can result from the fragmentation method chosen, as described above. For example, one skilled in the art recognizes that a genomic nucleic acid can be denatured during pH-based shearing or fragmenting via nicking endonucleases. Denaturation can occur either before, during, or after fragmentation. In addition, the use of pH or heat during the fragmenting step can result in denatured nucleic acid fragments. See, for example, McDonnell, “Antisepsis, disinfection, and sterilization: types, action, and resistance,” pg. 239 (2007).

Heat-based denaturing is the process by which double-stranded deoxyribonucleic acid unwinds and separates into single-stranded strands through the breaking of hydrogen bonding between the bases. Heat denaturation of a nucleic acid of an unknown sequence typically uses a temperature high enough to ensure denaturation of even nucleic acids having a very high GC content, e.g., 95° C.-98° C. in the absence of any chemical denaturant. It is well within the abilities of one of ordinary skill in the art to optimize the conditions (e.g., time, temperature, etc.) for denaturation of the nucleic acid. Temperatures significantly lower than 95° C. can also be used if the DNA contains nicks (and therefore sticky overhangs of low Tm) or sequence of sufficiently low Tm.

Denaturing nucleic acids with the use of pH is also well known in the art, and such denaturation can be accomplished using any method known in the art such as introducing a nucleic acid to high or low pH, low ionic strength, and/or heat, which disrupts base-pairing causing a double-stranded helix to dissociate into single strands. For methods of pH-based denaturation see, for example, Dore et al. Biophys J. 1969 November; 9(11): 1281-1311; A. M. Michelson The Chemistry of Nucleosides and Nucleotides, Academic Press, London and New York (1963).

Nucleic acids can also be denatured via electro-chemical means, for example, by applying a voltage to a nucleic acid within a solution by means of an electrode. Varying methods of denaturing by applying a voltage are discussed in detail in U.S. Pat. Nos. 6,197,508 and 5,993,611.

Molecular Inversion Probe Capture

Molecular inversion probe technology is used to detect or amplify particular nucleic acid sequences in complex mixtures. Use of molecular inversion probes has been demonstrated for detection of single nucleotide polymorphisms (Hardenbol et al. 2005 Genome Res 15:269-75) and for preparative amplification of large sets of exons (Porreca et al. 2007 Nat Methods 4:931-6, Krishnakumar et al. 2008 Proc Natl Acad Sci USA 105:9296-301). One of the main benefits of the method is in its capacity for a high degree of multiplexing, because generally thousands of targets may be captured in a single reaction containing thousands of probes.

In certain embodiments, molecular inversion probes include a universal portion flanked by two unique targeting arms. The targeting arms are designed to hybridize immediately upstream and downstream of a specific target sequence located on a genomic nucleic acid fragment. The molecular inversion probes are introduced to nucleic acid fragments to perform capture of target sequences located on the fragments. According to the invention, fragmenting aids in capture of target nucleic acid by molecular inversion probes. As described in greater detail herein, after capture of the target sequence (e.g., locus) of interest, the captured target may further be subjected to an enzymatic gap-filling and ligation step, such that a copy of the target sequence is incorporated into a circle. Capture efficiency of the MIP to the target sequence on the nucleic acid fragment can be improved by lengthening the hybridization and gap-filing incubation periods. (See, e.g., Turner E H, et al., Nat Methods. 2009 Apr. 6:1-2.).

In one embodiment of the present invention, a library of molecular inversion probes is generated, wherein the probes are used in capturing DNA of genomic regions of interests (e.g., SMN1, SMN2, control DNA). The library consists of a plurality of SMA oligonucleotide probes capable of capturing one or more genomic regions of interest (e.g., SMN1, SMN2 and control loci) within the samples to be tested.

The result of MIP capture as described above is a library of circular target probes, which then can be processed in a variety of ways. In one aspect, adaptors for sequencing can be attached during common linker-mediated PCR, resulting in a library with non-random, fixed starting points for sequencing. In another aspect, for preparation of a shotgun library, a common linker-mediated PCR is performed on the circle target probes, and the post-capture amplicons are linearly concatenated, sheared, and attached to adaptors for sequencing. Methods for shearing the linear concatenated captured targets can include any of the methods disclosed for fragmenting nucleic acids discussed above. In certain aspects, performing a hydrolysis reaction on the captured amplicons in the presence of heat is the desired method of shearing for library production.

It should be appreciated that aspects of the invention can involve varying the amounts of genomic nucleic acid and varying the amounts of MIP probes to reach a customized result. In some embodiments, the amount of genomic nucleic acid used per subject ranges from 1 ng to 10 μg (e.g., 500 ng to 5 μg). However, higher or lower amounts (e.g., less than 1 ng, more than 10 μg, 10-50 μg, 50-100 μg or more) may be used. In some embodiments, for each locus of interest, the amount of probe used per assay may be optimized for a particular application. In some embodiments, the ratio (molar ratio, for example measured as a concentration ratio) of probe to genome equivalent (e.g., haploid or diploid genome equivalent, for example for each allele or for both alleles of a nucleic acid target or locus of interest) ranges from 1/100, 1/10, 1/1, 10/1, 100/1, 1000/1. However, lower, higher, or intermediate ratios may be used.

In some embodiments, the amount of target nucleic acid and probe used for each reaction is normalized to avoid any observed differences being caused by differences in concentrations or ratios. In some embodiments, in order to normalize genomic DNA and probe, the genomic DNA concentration is read using a standard spectrophotometer or by fluorescence (e.g., using a fluorescent intercalating dye). The probe concentration may be determined experimentally or using information specified by the probe manufacturer.

Similarly, once a locus has been captured, it may be amplified and/or sequenced in a reaction involving one or more primers. The amount of primer added for each reaction can range from 0.1 pmol to 1 nmol, 0.15 pmol to 1.5 nmol (for example around 1.5 pmol). However, other amounts (e.g., lower, higher, or intermediate amounts) may be used.

In some embodiments, it should be appreciated that one or more intervening sequences (e.g., sequence between the first and second targeting arms on a MIP capture probe), identifier or tag sequences, or other probe sequences that are not designed to hybridize to a target sequence (e.g., a genomic target sequence) should be designed to avoid excessive complementarity (to avoid cross-hybridization) to target sequences or other sequences (e.g., other genomic sequences) that may be in a biological sample. For example, these sequences may be designed to have a sufficient number of mismatches with any genomic sequence (e.g., at least 5, 10, 15, or more mismatches out of 30 bases) or to have a Tm (e.g., a mismatch Tm) that is lower (e.g., at least 5, 10, 15, 20, or more degrees C. lower) than the hybridization reaction temperature.

It should be appreciated that a targeting arm as used herein may be designed to hybridize (e.g., be complementary) to either strand of a genetic locus of interest if the nucleic acid being analyzed is DNA (e.g., genomic DNA). However, in the context of MIP probes, whichever strand is selected for one targeting arm will be used for the other one. However, in the context of RNA analysis, it should be appreciated that a targeting arm should be designed to hybridize to the transcribed RNA. It also should be appreciated that MIP probes referred to herein as “capturing” a target sequence are actually capturing it by template-based synthesis rather than by capturing the actual target molecule (other than for example in the initial stage when the arms hybridize to it or in the sense that the target molecule can remain bound to the extended MIP product until it is denatured or otherwise removed).

It should be appreciated that in some embodiments a targeting arm may include a sequence that is complementary to one allele or mutation (e.g., a SNP or other polymorphism, a mutation, etc.) so that the probe will preferentially hybridize (and capture) target nucleic acids having that allele or mutation. However, in many embodiments, each targeting arm is designed to hybridize (e.g., be complementary) to a sequence that is not polymorphic in the subjects of a population that is being evaluated. This allows target sequences to be captured and/or sequenced for all alleles and then the differences between subjects (e.g., calls of heterozygous or homozygous for one or more loci) can be based on the sequence information and/or the frequency as described herein.

It should be appreciated that sequence tags (also referred to as barcodes) may be designed to be unique in that they do not appear at other positions within a probe or a family of probes and they also do not appear within the sequences being targeted. Thus they can be used to uniquely identify (e.g., by sequencing or hybridization properties) particular probes having other characteristics (e.g., for particular subjects and/or for particular loci).

It also should be appreciated that in some embodiments probes or regions of probes or other nucleic acids are described herein as including certain sequences or sequence characteristics (e.g., length, other properties, etc.). In addition, components (e.g., arms, central regions, tags, primer sites, etc., or any combination thereof) of such probes can include certain sequences or sequence characteristics that consist of one or more characteristics (e.g., length or other properties, etc.).

As disclosed herein, uniformity and reproducibility can be increased by designing multiple probes per target, such that each base in the target is captured by more than one probe. In some embodiments, the disclosure provides multiple MIPs per target to be captured, where each MIP in a set designed for a given target nucleic acid has a central region and a 5′ region and 3′ region (‘targeting arms’) which hybridize to (at least partially) different nucleic acids in the target nucleic acid (immediately flanking a subregion of the target nucleic acid). Thus, differences in efficiency between different targeting arms and fill-in sequences may be averaged across multiple MIPs for a single target, which results in more uniform and reproducible capture efficiency.

In some embodiments, the methods involve designing a single probe for each target (a target can be as small as a single base or as large as a kilobase or more of contiguous sequence).

It may be preferable, in some cases, to design probes to capture molecules (e.g., target nucleic acids or subregions thereof) having lengths in the range of 1-200 bp (as used herein, a by refers to a base pair on a double-stranded nucleic acid—however, where lengths are indicated in bps, it should be appreciated that single-stranded nucleic acids having the same number of bases, as opposed to base pairs, in length also are contemplated by the invention). However, probe design is not so limited. For example, probes can be designed to capture targets having lengths in the range of up to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 1000, or more bps, in some cases.

It is to be appreciated that the length of a capture molecule on a nucleic acid fragment (e.g., a target nucleic acid or subregion thereof) is selected based upon multiple considerations. For example, where analysis of a target involves sequencing, e.g., with a next-generation sequencer, the target length should typically match the sequencing read-length so that shotgun library construction is not necessary. However, it should be appreciated that captured nucleic acids may be sequenced using any suitable sequencing technique as aspects of the invention are not limited in this respect.

It is also to be appreciated that some target nucleic acids on a nucleic acid fragment are too large to be captured with one probe. Consequently, it may be necessary to capture multiple subregions of a target nucleic acid in order to analyze the full target.

In some embodiments, a sub-region of a target nucleic acid is at least 1 bp. In other embodiments, a subregion of a target nucleic acid is at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 bp or more. In other embodiments, a subregion of a target nucleic acid has a length that is up to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more percent of a target nucleic acid length.

The skilled artisan will also appreciate that consideration is made, in the design of MIPs, for the relationship between probe length and target length. In some embodiments, MIPs are designed such that they are several hundred basepairs (e.g., up to 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 bp or more) longer than corresponding target (e.g., subregion of a target nucleic acid, target nucleic acid). In some embodiments, lengths of subregions of a target nucleic acid may differ.

For example, if a target nucleic acid contains regions for which probe hybridization is not possible or inefficient, it may be necessary to use probes that capture subregions of one or more different lengths in order to avoid hybridization with problematic nucleic acids and capture nucleic acids that encompass a complete target nucleic acid.

Methods of the invention also provide for combining the method of fragmenting the nucleic acid prior to capture with other MIP capture techniques that are designed to increase target uniformity, reproducibility, and specificity. Other MIP capture techniques are shown in co-owned and pending application, U.S. patent application Ser. No. 13/266,862, “Methods and Compositions for Evaluating Genetic Markers.”

For example, multiple probes, e.g., MIPs, can be used to amplify each target nucleic acid. In some embodiments, the set of probes for a given target can be designed to ‘tile’ across the target, capturing the target as a series of shorter sub targets. In some embodiments, where a set of probes for a given target is designed to ‘tile’ across the target, some probes in the set capture flanking non-target sequence). Alternately, the set can be designed to ‘stagger’ the exact positions of the hybridization regions flanking the target, capturing the full target (and in some cases capturing flanking non-target sequence) with multiple probes having different targeting arms, obviating the need for tiling. The particular approach chosen will depend on the nature of the target set. For example, if small regions are to be captured, a staggered-end approach might be appropriate, whereas if longer regions are desired, tiling might be chosen. In all cases, the amount of bias-tolerance for probes targeting pathological loci can be adjusted by changing the number of different MIPs used to capture a given molecule.

Probes for MIP capture reactions may be synthesized on programmable microarrays because of the large number of sequences required. Because of the low synthesis yields of these methods, a subsequent amplification step is required to produce sufficient probe for the MIP amplification reaction. The combination of multiplex oligonucleotide synthesis and pooled amplification results in uneven synthesis error rates and representational biases. By synthesizing multiple probes for each target, variation from these sources may be averaged out because not all probes for a given target will have the same error rates and biases.

Barcode PCR

With these methods, a single copy of a specific target nucleic acid may be amplified to a level that can be sequenced. Further, the amplified segments created by an amplification process such as PCR may be, themselves, efficient templates for subsequent PCR amplifications.

Amplification or sequencing adapters or barcodes, or a combination thereof, may be attached to the fragmented nucleic acid. Such molecules may be commercially obtained, such as from Integrated DNA Technologies (Coralville, Iowa). In certain embodiments, such sequences are attached to the template nucleic acid molecule with an enzyme such as a ligase. Suitable ligases include T4 DNA ligase and T4 RNA ligase, available commercially from New England Biolabs (Ipswich, Mass.). The ligation may be blunt ended or via use of complementary overhanging ends. In certain embodiments, following fragmentation, the ends of the fragments may be repaired, trimmed (e.g. using an exonuclease), or filled (e.g., using a polymerase and dNTPs) to form blunt ends. In some embodiments, end repair is performed to generate blunt end 5′ phosphorylated nucleic acid ends using commercial kits, such as those available from Epicentre Biotechnologies (Madison, Wis.). Upon generating blunt ends, the ends may be treated with a polymerase and dATP to form a template independent addition to the 3′-end and the 5′-end of the fragments, thus producing a single A overhanging. This single A can guide ligation of fragments with a single T overhanging from the 5′-end in a method referred to as T-A cloning. Alternatively, because the possible combination of overhangs left by the restriction enzymes are known after a restriction digestion, the ends may be left as-is, i.e., ragged ends. In certain embodiments double stranded oligonucleotides with complementary overhanging ends are used.

In certain embodiments, one or more bar code is attached to each, any, or all of the fragments. A bar code sequence generally includes certain features that make the sequence useful in sequencing reactions. The bar code sequences are designed such that each sequence is correlated to a particular portion of nucleic acid, allowing sequence reads to be correlated back to the portion from which they came. Methods of designing sets of bar code sequences is shown for example in U.S. Pat. No. 6,235,475, the contents of which are incorporated by reference herein in their entirety. In certain embodiments, the bar code sequences range from about 5 nucleotides to about 15 nucleotides. In a particular embodiment, the bar code sequences range from about 4 nucleotides to about 7 nucleotides. In certain embodiments, the bar code sequences are attached to the template nucleic acid molecule, e.g., with an enzyme. The enzyme may be a ligase or a polymerase, as discussed above. Attaching bar code sequences to nucleic acid templates is shown in U.S. Pub. 2008/0081330 and U.S. Pub. 2011/0301042, the content of each of which is incorporated by reference herein in its entirety. Methods for designing sets of bar code sequences and other methods for attaching bar code sequences are shown in U.S. Pat. Nos. 6,138,077; 6,352,828; 5,636,400; 6,172,214; 6,235,475; 7,393,665; 7,544,473; 5,846,719; 5,695,934; 5,604,097; 6,150,516; RE39,793; 7,537,897; 6172,218; and 5,863,722, the content of each of which is incorporated by reference herein in its entirety. After any processing steps (e.g., obtaining, isolating, fragmenting, amplification, or barcoding), nucleic acid can be sequenced.

Sequencing

Sequencing may be by any method known in the art. DNA sequencing techniques include classic dideoxy sequencing reactions (Sanger method) using labeled terminators or primers and gel separation in slab or capillary, sequencing by synthesis using reversibly terminated labeled nucleotides, pyrosequencing, 454 sequencing, Illumina/Solexa sequencing, allele specific hybridization to a library of labeled oligonucleotide probes, sequencing by synthesis using allele specific hybridization to a library of labeled clones that is followed by ligation, real time monitoring of the incorporation of labeled nucleotides during a polymerization step, polony sequencing, and SOLiD sequencing. Separated molecules may be sequenced by sequential or single extension reactions using polymerases or ligases as well as by single or sequential differential hybridizations with libraries of probes.

A sequencing technique that can be used includes, for example, Illumina sequencing. Illumina sequencing is based on the amplification of DNA on a solid surface using fold-back PCR and anchored primers. Genomic DNA is fragmented, and adapters are added to the 5′ and 3′ ends of the fragments. DNA fragments that are attached to the surface of flow cell channels are extended and bridge amplified. The fragments become double stranded, and the double stranded molecules are denatured. Multiple cycles of the solid-phase amplification followed by denaturation can create several million clusters of approximately 1,000 copies of single-stranded DNA molecules of the same template in each channel of the flow cell. Primers, DNA polymerase and four fluorophore-labeled, reversibly terminating nucleotides are used to perform sequential sequencing. After nucleotide incorporation, a laser is used to excite the fluorophores, and an image is captured and the identity of the first base is recorded. The 3′ terminators and fluorophores from each incorporated base are removed and the incorporation, detection and identification steps are repeated. Sequencing according to this technology is described in U.S. Pat. Nos. 7,960,120; 7,835,871; 7,232,656; 7,598,035; 6,911,345; 6,833,246; 6,828,100; 6,306,597; 6,210,891; U.S. Pub. 2011/0009278; U.S. Pub. 2007/0114362; U.S. Pub. 2006/0292611; and U.S. Pub. 2006/0024681, each of which are incorporated by reference in their entirety.

Sequencing generates a plurality of reads. Reads generally include sequences of nucleotide data less than about 150 bases in length, or less than about 90 bases in length. In certain embodiments, reads are between about 80 and about 90 bases, e.g., about 85 bases in length. In some embodiments, these are very short reads, i.e., less than about 50 or about 30 bases in length.

Data Analysis

The sequence reads are analyzed to determine copy number states of genomic regions of interest. A set of sequence reads can be analyzed by any suitable method known in the art. For example, in some embodiments, sequence reads are analyzed by hardware or software provided as part of a sequence instrument. In some embodiments, individual sequence reads are reviewed by sight (e.g., on a computer monitor). A computer program may be written that pulls an observed genotype from individual reads. In certain embodiments, analyzing the reads includes assembling the sequence reads and then genotyping the assembled reads.

Sequence assembly can be done by methods known in the art including reference-based assemblies, de novo assemblies, assembly by alignment, or combination methods. Assembly can include methods described in U.S. Pat. No. 8,209,130 titled Sequence Assembly by Porecca and Kennedy, the contents of each of which are hereby incorporated by reference in their entirety for all purposes. In some embodiments, sequence assembly uses the low coverage sequence assembly software (LOCAS) tool described by Klein, et al., in LOCAS-A low coverage sequence assembly tool for re-sequencing projects, PLoS One 6(8) article 23455 (2011), the contents of which are hereby incorporated by reference in their entirety. Sequence assembly is described in U.S. Pat. Nos. 8,165,821; 7,809,509; 6,223,128; U.S. Pub. 2011/0257889; and U.S. Pub. 2009/0318310, the contents of each of which are hereby incorporated by reference in their entirety.

As part of the analysis and determination of copy number states and subsequent identification of copy number variation, the sequence read counts for genomic regions of interest are normalized based on internal controls. In particular, an intra-sample normalization is performed to control for variable sequencing depths between samples. The sequence read counts for each genomic region of interest within a sample will be normalized according to the total read count across all control references within the sample.

After normalizing read counts for both the genomic regions of interest and control references, copy number states may be determined. In one embodiment, the normalized values for each sample of interest will be compared to the normalized values for a control sample. A ratio, for example, may be generated based on the comparison, wherein the ratio is indicative of copy number and further determinative of any copy number variation. In the event that the determined copy number of a genomic region of interest of a particular sample falls within a tolerable level (as determined by ratio between test and control samples), it can be determined that genomic region of interest does not present copy number variation and thus the patient is at low risk for being a carrier of a condition or disease associated with such. In the event that the determined copy number of a genomic region of interest of a particular sample falls outside of a tolerable level, it can be determined that genomic region of interest does present copy number variation and thus the patient is at risk for being a carrier of a condition or disease associated with such.

EXAMPLE

Determination of Copy Number State of SMN1

The following example shows a preferred method of practicing the invention.

A total of approximately 28 samples were collected from a patient to determine carrier status with respect to spinal muscular atrophy (SMA). In one embodiment, genomic DNA was extracted from whole human blood using a Gentra Puregene Blood Kit and following the Puregene protocol for DNA Purification from Whole Blood (Qiagen). The protocol can be scaled (i.e. amount of solution, duration) to accommodate the desired amount of whole genomic DNA. The samples were collected via any methods previously described herein. Further, it should be noted that the DNA could be collected from other types of samples (e.g., tissue, mucous, etc.).

Of the 28 samples, there is 1 water negative control and 7 control DNA samples and 20 test samples. Each of the control samples includes two or more genomic regions of interest (e.g. loci) having known (or stable) copy numbers. The details of each control sample are included in Table 1 below:

TABLE 1 Control Samples Control Sample ID Locus Number of Loci Copy Number Controls 1-4 (each) Control 17 2 SMN1 5 2 SMN2 5 2 Control 5 Control 17 2 SMN1 5 0 Control 6 Control 17 2 SMN1 5 1 Control 7 Control 17 2 SMN1 5  3+

Control samples 1-4 each include control loci and survival motor neuron genes (SMN), including telomeric SMN (SMN1) and centromeric SMN (SMN2) genes. There are a total of 17 control loci, 5 SMN1, and 5 SMN2, all of which have a known copy number of 2. Control sample 5 includes 17 control loci, each having a known copy number of 2, and 5 SMN1, each having a known copy number of 0. Control sample 6 includes 17 control loci, each having a known copy number of 2, and 5 SMN1, each having a known copy number of 1. Control sample 7 includes 17 control loci, each having a known copy number of 2, and 5 SMN1, each having a known copy number of 3 or more. As described in greater detail herein, inclusion of the control samples into the overall sample size allows identification of copy number states and any copy number variation of SMN1 and/or SMN2 captured from the test samples, thereby allowing subsequent determination of carrier status of a patient based on the copy number variation.

Each sample was first normalized by any know normalizing techniques. The normalized samples were then fragmented and/or denatured in preparation for hybridizing with molecular inversion probes. The genomic DNA of each sample was fragmented/denatured by any known method or technique sufficient to fragment genomic DNA.

Once isolated, MIP capture probes were hybridized to isolated fragmented genomic DNA in each sample by introducing capture probe mix into each sample well. In particular, the capture probe mix will generally include a plurality of SMA molecular inversion probes that are capable of binding to one or more of the genomic regions of interest (e.g., SMN1 and SMN2) or the control DNA. A library of molecular inversion probes was generated. The library may include a variety of different probe configurations. For example, one or more probes are capable of hybridizing specifically to the control loci and one or more probes are capable of hybridizing only to SMN1 or SMN2. Of those probes specific to SMN1 or SMN2, some are capable of producing sequences specific to that paralog while some are not capable of producing paralog-specific sequences. It should be noted that some methods described herein may utilized only one of these options. The library may also include one or more probes capable of hybridizing nonspecifically to both SMN1 and SMN2. During the sequencing process, described in greater detail herein, the non-specificity may be resolved by reading out the sequence captured by the non-specific probe, wherein the sequence may generally be specific to either SMN1 or SMN2 (a variant present in the captured sequence that is specific for one or the other paralog).

Diluted probes were introduced to the isolated fragmented genomic DNA in each sample and the isolated whole genomic DNA was incubated in the diluted probe mix to promote hybridization. The time and temperature for incubation may be based on any known hybridization protocol, sufficient to result in hybridization of the probes to the DNA. After capture of the genomic region of interest (e.g., SMN1, SMN2) the captured region is subjected to an enzymatic gap-filling and ligation step, in accordance with any known methods or techniques, including those generally described herein. The captured material may further be purified.

The purified captured DNA is then amplified by any known amplification methods or techniques. In one embodiment, the purified captured DNA was amplified using barcode-based PCR, in accordance with methods previously described herein. The resulting barcodes PCRs for each sample are then combined into a master pool and quantified.

After PCR, portions of the PCR reactions for each sample were pooled and purified, then quantified. In particular, the PCR reactions for all samples were pooled in equal volumes into one master pool. The master sample pool was then purified via a PCR cleanup protocol according to manufacturer's instructions. For example, Qiagen QIAquick PCR cleanup kit (Qiagen) was used to purify the sample pool, in accordance with the manufacturer's instructions.

The purified pool was then run on a microfluidics-based platform for sizing, quantification and quality control of DNA, RNA, proteins and cells. In particular, the purified pool and control samples (pre-purification), were run on Agilent Bioanalyzer for the detection and quantification of CF probe products and SMA probe products.

Next, the sample pool is prepared for sequencing. In a preferred embodiment, Illumina sequencing techniques were used. Prior to sequencing, the sample pool was reduced to 2 nM by diluting with 1×TE. Template DNA for cluster generation was prepared by combining 10 uL of 0.1 N NaOH with 10 uL of 2 nM DNA library (sample pool) and incubating said mixture at room temperature for 5 min. The mixture was then mixed with 980 uL of HT1 buffer (Illumina), thereby reducing the denatured library to a concentration of 20 pM. This mixture was then mixed (e.g., inversion) and pulse centrifuged. Next, 225 uL of the 20 pM library was mixed with 775 uL of HT1 buffer to reduce the library pool to a concentration of 4.5 pM. The library pool having a concentration of 4.5 pM is used for on-board clustering in the sequencing described below.

The sequencing, and subsequent analysis, was carried out on the HiSeq 2500/1500 system sold by Illumina, Inc. (San Diego, Calif.). Sequencing was carried out with the TruSeq Rapid PE Cluster Kit and TruSeq Rapid SBS 200 cycle kit (Illumina) and in accordance with manufacturer's instructions. In addition to the reagents and mixes included within the kits, additional reagents were prepared for genomic read sequencing primers and reverse barcode sequencing primers.

The library pool undergoes sequencing under paired-end, dual-index run conditions. Sequencing generates a plurality of reads. Reads generally include sequences of nucleotide data less than about 150 bases in length, or less than about 90 bases in length. In certain embodiments, reads are between about 80 and about 90 bases, e.g., about 85 bases in length. In some embodiments, these are very short reads, i.e., less than about 50 or about 30 bases in length. After obtaining sequence reads, they are further processed as illustrated in FIG. 1.

FIG. 1 is a flow diagram illustrating one embodiment of a method for determining copy number state of one of more genomic regions of interest in a sample. The method 100 includes obtaining sequence reads (operation 102) and normalizing read counts (operation 104). As described in greater detail herein, read counts for a genomic region of interest are normalized with respect to an internal control DNA. The method 100 further includes comparing normalized read counts to the internal control DNA (operation 106), thereby obtaining a ratio. The method further includes determining a copy number state of the genomic region of interest (operation 108) based on the comparison, specifically the ratio.

The plurality of reads generated by the sequencing method described above are analyzed to determine copy number states, and ultimately copy number variation, in any of the genomic regions of interest (e.g., SMN1 and SMN2) that would necessarily indicate the presence of an autosomal recessive trait in which copy number variation is diagnostic (e.g., spinal muscular atrophy). Analysis of the read counts is carried out using Illumina's HiSeq BclConverter software. Files (e.g., qSeq files) may be generated for both the genomic and barcode reads. In particular, in accordance with one method of the present invention, genomic read data for each sample is split based upon the barcode reads, which yields separate FASTQ files for each sample.

Analysis of the sequence results has a first step of normalizing the read counts for the SMN1 and SMN2 loci (genetic regions of interest for SMA). The read counts are normalized by dividing the read counts with a read count sum for a control. The read count sum generally includes all 17 SMA control loci of the 7 control samples. Then, the average normalized values for a set of pre-determined or empirically-identified (e.g., by analysis iteration) wild-type control samples are obtained. Then the normalized read counts for each test sample (each locus) are compared to the normalized read counts for each of the control samples, thereby obtaining a ratio of normalized read count of test samples/normalized read count of controls.

Based on the ratios, loci copy numbers may be called as follows: a ratio of <0.1 will be called a copy number state of 0; a ratio between 0.1 and 0.8 will be called a copy number state of 1; a ratio between 0.8 and 1.25 will be called a copy number state of 2; and a ratio of >1.25 will be called a copy number state of 3+.

The determined copy numbers can then be used to determine the carrier status of an individual from which the sample was obtained (i.e. whether the patient is a carrier of the disease). In particular, if the copy number state is determined to vary from the normal copy state (e.g., CN is 0, 1 or 3+), it is indicative the condition (e.g., carrier of SMA).

Additionally, or alternatively, upon initial normalization of the read counts for the test samples and control samples, the resulting vector of normalized frequencies may include x=[f1, f2, . . . , fn] which correspond to the frequencies of each of the loci being queried (test and control). The normalized frequencies from either a single control sample or a “synthetic” control (average of multiple control samples) y=[g1, g2, . . . , gn] may be used to calculate the copy number of each locus interrogated c=x./y=[f1/g1, f2/g2, . . . , fn/gn].

Functions described above can be implemented using software, hardware, firmware, hardwiring, or combinations of any of these. Any of the software can be physically located at various positions, including being distributed such that portions of the functions are implemented at different physical locations.

As one skilled in the art would recognize as necessary or best-suited for performance of the methods of the invention, a computer system 200 for implementing some or all of the described inventive methods can include one or more processors (e.g., a central processing unit (CPU) a graphics processing unit (GPU), or both), main memory and static memory, which communicate with each other via a bus.

In an exemplary embodiment shown in FIG. 2, system 200 includes a sequencer 201 with a data acquisition module 205 to obtain sequence read data. The sequencer 201 may optionally include or be operably coupled to its own, e.g., dedicated, sequencer computer 233 (including an input/output mechanism 237, one or more of processor 241, and memory 245). Additionally or alternatively, the sequencer 201 may be operably coupled to a server 213 or computer 249 (e.g., laptop, desktop, or tablet) via a network 209. As previously described herein, the sequencer 201 may include the HiSeq 2500/1500 system sold by Illumina, Inc. (San Diego, Calif.).

The computer 249 includes one or more processors 259 and memory 263 as well as an input/output mechanism 254. Where methods of the invention employ a client/server architecture, steps of methods of the invention may be performed using the server 213, which includes one or more of processors 221 and memory 229, capable of obtaining data, instructions, etc., or providing results via an interface module 225 or providing results as a file 217. The server 213 may be engaged over the network 209 by the computer 249 or the terminal 267, or the server 213 may be directly connected to the terminal 267, which can include one or more processors 275 and memory 279, as well as an input/output mechanism 271.

The system or machines 200 according to the invention may further include, for any of I/O 249, 237, or 271, a video display unit (e.g., a liquid crystal display (LCD) or a cathode ray tube (CRT)). Computer systems or machines used to implement some or all of the invention can also include an alphanumeric input device (e.g., a keyboard), a cursor control device (e.g., a mouse), a disk drive unit, a signal generation device (e.g., a speaker), a touchscreen, an accelerometer, a microphone, a cellular radio frequency antenna, and a network interface device, which can be, for example, a network interface card (NIC), Wi-Fi card, or cellular modem.

Memory 263, 245, 279, or 229 can include one or more machine-readable devices on which is stored one or more sets of instructions (e.g., software) which, when executed by the processor(s) of any one of the disclosed computers can accomplish some or all of the methodologies or functions described herein. The software may also reside, completely or at least partially, within the main memory and/or within the processor during execution thereof by the computer system.

While the machine-readable devices can in an exemplary embodiment be a single medium, the term “machine-readable device” should be taken to include a single medium or multiple media (e.g., a centralized or distributed database, and/or associated caches and servers) that store the one or more sets of instructions and/or data. These terms shall also be taken to include any medium or media that are capable of storing, encoding, or holding a set of instructions for execution by the machine and that cause the machine to perform any one or more of the methodologies of the present invention. These terms shall accordingly be taken to include, but not be limited to one or more solid-state memories (e.g., subscriber identity module (SIM) card, secure digital card (SD card), micro SD card, or solid-state drive (SSD)), optical and magnetic media, and/or any other tangible storage medium or media.

The invention solves problems associated with current carrier screening assays by providing molecular inversion probes for capturing at least one genomic region known or suspected to be associated with a disease and subsequently sequencing the captured DNA to determine the copy number state of the captured DNA. In certain aspects, the captured DNA may be sequenced by known high-throughput sequence methods or techniques. The carrier status for the disease can then be determined based on the identified copy number state. In particular, the copy number state may be indicative of whether the patient is a carrier of a particular disease or condition for which copy number variation is diagnostic, such as an autosomal recessive trait (e.g., spinal muscular atrophy). For example, it can be determined whether copy number variation exists in the genomic regions of interest based on the identified copy number, thereby providing a method for determining whether the patient is a carrier of such an autosomal recessive trait.

Accordingly, the invention overcomes the problems of current carrier screening assays, particularly MLPA-based assays, based, at least in part, on compatibility with automated high-throughput screening. In particular, the invention provides the sensitivity and specificity for detection of copy number variation in SMN1 and/or SMN2, similar to MLPA-based methods, by utilizing molecular inversion probes. Additionally, by using high-throughput screening methods, the invention allows detection of deleterious SMN1 point mutations and indels that would otherwise be missed by MLPA and related approaches, thereby providing more reliable and accurate diagnosis.

INCORPORATION BY REFERENCE

References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.

EQUIVALENTS

Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof. 

What is claimed is:
 1. A method for determining copy number, the method comprising: obtaining a sample from a patient, the sample comprising genomic DNA that includes a genomic region suspected of having an altered copy number and an internal control DNA having a stable copy number; fragmenting the genomic DNA to yield target nucleic acid comprising fragments of the genomic region and fragments of the internal control DNA; providing a plurality of molecular inversion probes capable of capturing the fragments of the genomic region and the fragments of the internal control DNA; exposing the target nucleic acid to the plurality of molecular inversion probes; capturing DNA that binds said molecular inversion probes; sequencing the captured DNA to produce target sequence reads and control sequence reads; enumerating target read counts from the target sequence reads and control read counts from the control sequence reads; normalizing the target read counts with respect to the control read counts; comparing the normalized target read counts to normalized read counts for a control diploid locus; and determining a copy number state of the genomic region; wherein one or more of the enumerating, normalizing, comparing, and determining steps is performed using a computer system comprising a processor couple to a memory.
 2. The method of claim 1, wherein said determining step comprises determining differences between the normalized target read counts and the normalized read counts for the control diploid locus based upon the comparison.
 3. The method of claim 1, wherein the normalized read counts for the control diploid locus are obtained from a control sample that is different from the sample.
 4. The method of claim 3, wherein the normalized read counts for the control diploid locus are obtained from a synthetic nucleic acid in the control sample.
 5. The method of claim 1, wherein the genomic region comprises a first gene and a second gene, wherein the first and second genes are homologs, orthologs, or paralogs.
 6. The method of claim 5, wherein the first gene is SMN1 and the second gene is SMN2.
 7. The method of claim 6, further comprising the step of diagnosing a carrier phenotype for spinal muscular atrophy.
 8. The method of claim 1, wherein the sequencing step comprises a next-generation sequencing method.
 9. The method of claim 1, wherein the determining step comprises determining a difference between the copy number state of the genomic region and a copy number distribution encompassing a plurality of stable control loci.
 10. The method of claim 1, wherein the sample is blood.
 11. A method of determining copy number between two paralogous genes, the method comprising the steps of: obtaining a sample from a patient, the sample comprising genomic DNA that includes a first gene, a second gene, and an internal control genetic locus, wherein the first gene and the second gene are paralogs; fragmenting the genomic DNA to yield target nucleic acid comprising fragments of the first gene, the second gene, and the internal control genetic locus; providing a plurality of molecular inversion probes capable of capturing the fragments of the first gene, the second gene, and the internal control genetic locus; exposing the target nucleic acid to the plurality of molecular inversion probes; capturing DNA that hybridizes to one or more of the plurality of molecular inversion probes; sequencing the DNA; enumerating read counts from the sequenced DNA; normalizing the read counts for each of the first gene and the second gene with respect to the internal control genetic locus; comparing normalized read counts for each of the first gene and the second gene to normalized read counts for a control sample with a known number of copies of the first gene and the second gene; and determining relative copy number of the first gene and the second gene based upon the comparing step; wherein one or more of the enumerating, normalizing, comparing, and determining steps is performed using a computer system comprising a processor couple to a memory.
 12. The method of claim 11, wherein the first gene is SMN1 and the second gene is SMN2.
 13. The method of claim 11, wherein the internal control genetic locus has a stable copy number.
 14. The method of claim 11, further comprising reporting carrier status for one or more conditions.
 15. The method of claim 11, further comprising determining carrier status for spinal muscular atrophy.
 16. The method of claim 15, further comprising determining carrier status for at least one other autosomal recessive trait.
 17. The method of claim 16, wherein the at least one other autosomal recessive trait is selected from cystic fibrosis, sickle cell anemia, Tay-Sachs disease, familial hyperinsulinism, Canavan Disease, Maple Syrup Urine Disease, Bloom's Syndrome, Usher Syndrome type IIIA, dihydrolipoamide dehydrogenase deficiency, Fanconi anemia group C, familial dysautonomia, Mucolipidosis Type IV, Usher Syndrome Type IV, Nieman-Pick disease type A/B, Walker Warburg syndrome, and Joubert Syndrome. 